Impact of Phosphodiesterase-3 Inhibitor and Prostacyclin Analogue Combination on Pulmonary Hemodynamics in Acyanotic Congenital Heart Disease Patients with Pulmonary Hypertension: A Randomized Controlled Trial [PDF]
International Journal of BiomedicineBackground: Acyanotic congenital heart disease (ACHD) with left-to-right shunting frequently presents with pulmonary hypertension (PH), especially in developing countries where treatment options are often limited and costly.
Sefri Noventi Sofia +5 more
doaj +1 more source
The role of endothelin-1 in pulmonary arterial hypertension. [PDF]
, 2014 Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile,
Chester, AH, Yacoub, MH
core +1 more source
ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial. [PDF]
Nat Commun, 2023 Hu Y +20 more
europepmc +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr +15 more
wiley +1 more source
Effects of a Phosphodiesterase inhibitor on the Browning of Adipose Tissue in Mice. [PDF]
Biomedicines, 2022 Seo DH +6 more
europepmc +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Avanafil for treatment of erectile dysfunction: review of its potential
Vascular Health and Risk Management, 2012 Ryan M Burke,1 Jeffery D Evans21The University of Louisiana at Monroe College of Pharmacy, Monroe, LA, 2The University of Louisiana at Monroe College of Pharmacy, Shreveport, LA, USAAbstract: Avanafil is a medication that was recently approved by the US ...
Burke RM, Evans JD
doaj
Stronger inflammatory/cytotoxic T cell response in women identified by microarray analysis [PDF]
, 2008 Women develop chronic inflammatory autoimmune diseases like lupus more often than men. The mechanisms causing the increased susceptibility are incompletely understood, although estrogen is believed to contribute.
Anura Hewagama +4 more
core +1 more source
Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis. [PDF]
Saudi Pharm J, 2022 Chen Z +7 more
europepmc +1 more source
167: Modulation of Micturition Reflex by Phosphodiesterase 4 Inhibitor Roupram in Anesthetized Rats [PDF]
, 2006 Yu Zhong +4 more
openalex +1 more source